JP2022514348A - チオール多重リンカーを有するadc - Google Patents

チオール多重リンカーを有するadc Download PDF

Info

Publication number
JP2022514348A
JP2022514348A JP2021535547A JP2021535547A JP2022514348A JP 2022514348 A JP2022514348 A JP 2022514348A JP 2021535547 A JP2021535547 A JP 2021535547A JP 2021535547 A JP2021535547 A JP 2021535547A JP 2022514348 A JP2022514348 A JP 2022514348A
Authority
JP
Japan
Prior art keywords
group
antibody
drug
thiol
mla
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2021535547A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022514348A5 (cg-RX-API-DMAC7.html
Inventor
スコット ジェフリー
クン-パーン ワング
Original Assignee
シージェン インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by シージェン インコーポレイテッド filed Critical シージェン インコーポレイテッド
Publication of JP2022514348A publication Critical patent/JP2022514348A/ja
Publication of JP2022514348A5 publication Critical patent/JP2022514348A5/ja
Priority to JP2024163811A priority Critical patent/JP2024178320A/ja
Ceased legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/68031—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being an auristatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6889—Conjugates wherein the antibody being the modifying agent and wherein the linker, binder or spacer confers particular properties to the conjugates, e.g. peptidic enzyme-labile linkers or acid-labile linkers, providing for an acid-labile immuno conjugate wherein the drug may be released from its antibody conjugated part in an acidic, e.g. tumoural or environment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
    • C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/36—Seven-membered rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2021535547A 2018-12-21 2019-12-20 チオール多重リンカーを有するadc Ceased JP2022514348A (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2024163811A JP2024178320A (ja) 2018-12-21 2024-09-20 チオール多重リンカーを有するadc

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862783582P 2018-12-21 2018-12-21
US201862783707P 2018-12-21 2018-12-21
US62/783,582 2018-12-21
US62/783,707 2018-12-21
PCT/US2019/068178 WO2020132655A1 (en) 2018-12-21 2019-12-20 Adcs with thiol multiplex linkers

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2024163811A Division JP2024178320A (ja) 2018-12-21 2024-09-20 チオール多重リンカーを有するadc

Publications (2)

Publication Number Publication Date
JP2022514348A true JP2022514348A (ja) 2022-02-10
JP2022514348A5 JP2022514348A5 (cg-RX-API-DMAC7.html) 2022-12-20

Family

ID=71101991

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2021535547A Ceased JP2022514348A (ja) 2018-12-21 2019-12-20 チオール多重リンカーを有するadc
JP2024163811A Pending JP2024178320A (ja) 2018-12-21 2024-09-20 チオール多重リンカーを有するadc

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2024163811A Pending JP2024178320A (ja) 2018-12-21 2024-09-20 チオール多重リンカーを有するadc

Country Status (12)

Country Link
US (1) US20220040320A1 (cg-RX-API-DMAC7.html)
EP (1) EP3897734A4 (cg-RX-API-DMAC7.html)
JP (2) JP2022514348A (cg-RX-API-DMAC7.html)
KR (1) KR20210141918A (cg-RX-API-DMAC7.html)
CN (1) CN113543812A (cg-RX-API-DMAC7.html)
AU (1) AU2019403552A1 (cg-RX-API-DMAC7.html)
CA (1) CA3122316A1 (cg-RX-API-DMAC7.html)
IL (1) IL284147A (cg-RX-API-DMAC7.html)
MX (1) MX2021007548A (cg-RX-API-DMAC7.html)
SG (1) SG11202106122QA (cg-RX-API-DMAC7.html)
TW (1) TW202039008A (cg-RX-API-DMAC7.html)
WO (1) WO2020132655A1 (cg-RX-API-DMAC7.html)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026501849A (ja) * 2023-01-17 2026-01-16 イーライ リリー アンド カンパニー 治療薬の持続送達のための新規リンカー

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2021251875A1 (en) * 2020-04-10 2022-11-03 Seagen Inc. Charge variant linkers
IL317037A (en) * 2022-05-18 2025-01-01 Systimmune Inc Ligand-drug conjugate and its uses
LT4601703T (lt) 2023-04-18 2026-06-25 Astrazeneca Ab Konjugatai, apimantys atskeliamuosius jungtukus

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007132998A1 (en) * 2006-05-12 2007-11-22 Korea Research Institute Of Bioscience And Biotechnology Linker molecules for substrate surface treatment and specific protein immobilization, and method for preparing the same
WO2008147481A1 (en) * 2007-02-09 2008-12-04 Northeastern University Precision-guided nanoparticle systems for drug delivery
JP2015521187A (ja) * 2012-05-15 2015-07-27 シアトル ジェネティクス,インコーポレイティド 自己安定化リンカー結合体
US20150231285A1 (en) * 2013-09-18 2015-08-20 Institute Of Nuclear Energy Research Atomic Energy Council, Executive Yuan Radiolabeled active targeting pharmaceutical composition and the use thereof
WO2016025752A1 (en) * 2014-08-14 2016-02-18 Prolynx Llc Reagents for thiol conjugation and conjugates formed therefrom

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0871490B1 (en) * 1995-12-22 2003-03-19 Bristol-Myers Squibb Company Branched hydrazone linkers
EP0941120A4 (en) * 1996-11-05 2004-08-18 Bristol Myers Squibb Co BRANCHED PEPTIDLINKERS
DE10048417A1 (de) * 2000-09-29 2002-04-11 Roche Diagnostics Gmbh Verbindungen mit verzweigtem Linker
US6821529B2 (en) * 2001-09-05 2004-11-23 Deanna Jean Nelson Oligo(ethylene glycoll)-terminated 1,2-dithiolanes and their conjugates useful for preparing self-assembled monolayers
WO2012024613A1 (en) * 2010-08-19 2012-02-23 Wintrance Corporation Synergistic biomolecule-polymer conjugates
EP3842074A1 (en) * 2010-09-29 2021-06-30 Philogen S.p.A. Protein-drug conjugates
CN104640572B (zh) * 2012-05-15 2018-04-27 索伦托医疗有限公司 药物偶联物,偶联方法,及其用途
PL2872157T3 (pl) * 2012-07-12 2020-07-13 Hangzhou Dac Biotech Co., Ltd Koniugaty wiążących komórkę cząsteczek ze środkami cytotoksycznymi
JP2016531915A (ja) * 2013-08-28 2016-10-13 ステムセントリックス, インコーポレイテッド 部位特異的抗体コンジュゲーション方法および組成物
PT3057585T (pt) * 2013-10-15 2020-10-21 Seagen Inc Fármaco-ligadores peguilados para farmacocinética melhorada de conjugados de fármaco-ligando
US11135307B2 (en) * 2016-11-23 2021-10-05 Mersana Therapeutics, Inc. Peptide-containing linkers for antibody-drug conjugates
AU2021251875A1 (en) * 2020-04-10 2022-11-03 Seagen Inc. Charge variant linkers

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007132998A1 (en) * 2006-05-12 2007-11-22 Korea Research Institute Of Bioscience And Biotechnology Linker molecules for substrate surface treatment and specific protein immobilization, and method for preparing the same
WO2008147481A1 (en) * 2007-02-09 2008-12-04 Northeastern University Precision-guided nanoparticle systems for drug delivery
JP2015521187A (ja) * 2012-05-15 2015-07-27 シアトル ジェネティクス,インコーポレイティド 自己安定化リンカー結合体
US20150231285A1 (en) * 2013-09-18 2015-08-20 Institute Of Nuclear Energy Research Atomic Energy Council, Executive Yuan Radiolabeled active targeting pharmaceutical composition and the use thereof
WO2016025752A1 (en) * 2014-08-14 2016-02-18 Prolynx Llc Reagents for thiol conjugation and conjugates formed therefrom

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2026501849A (ja) * 2023-01-17 2026-01-16 イーライ リリー アンド カンパニー 治療薬の持続送達のための新規リンカー

Also Published As

Publication number Publication date
AU2019403552A1 (en) 2021-06-17
MX2021007548A (es) 2021-12-10
CN113543812A (zh) 2021-10-22
TW202039008A (zh) 2020-11-01
EP3897734A1 (en) 2021-10-27
WO2020132655A1 (en) 2020-06-25
KR20210141918A (ko) 2021-11-23
US20220040320A1 (en) 2022-02-10
EP3897734A4 (en) 2022-12-07
IL284147A (en) 2021-08-31
SG11202106122QA (en) 2021-07-29
CA3122316A1 (en) 2020-06-25
JP2024178320A (ja) 2024-12-24

Similar Documents

Publication Publication Date Title
KR102923527B1 (ko) 생체활성 분자 접합체, 이의 제조 방법 및 용도
TWI811726B (zh) 改良配體-藥物結合物之藥物動力學之聚乙二醇化藥物連接子
JP2023071996A (ja) 多剤抗体薬物コンジュゲート
JP2024096335A (ja) 親水性抗体-薬物コンジュゲート
CN106255513B (zh) 用于药物偶联物的含磺酰胺连接系统
TW202203978A (zh) 電荷可變連接子
KR20220079606A (ko) 캄프토테신 펩티드 접합체
JP2022105640A (ja) 四級化チューブリシン化合物の複合体
TW202010498A (zh) 喜樹鹼肽結合物
KR20210053871A (ko) 캄프토테신 접합체
JP2024520562A (ja) アントラサイクリン抗体コンジュゲート
JP2024178320A (ja) チオール多重リンカーを有するadc
CN107530422A (zh) Cd48抗体和其缀合物
TW202241522A (zh) 免疫刺激化合物及結合物
TW202417053A (zh) 免疫刺激抗體-藥物結合物
CN115052663A (zh) Alk5抑制剂缀合物及其用途
TW202412762A (zh) 奧瑞他汀衍生物及其結合物
HK40106962A (en) Anthracycline antibody conjugates
WO2026074296A1 (en) Linkers and protein and peptide conjugates incorporating the same
TW202535940A (zh) 化學治療化合物及使用方法
HK40097386A (en) Multi-drug antibody drug conjugates
HK40091718A (en) Charge variant linkers

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20221212

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20221212

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20230705

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20231122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20231204

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240301

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240412

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20240521

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240920

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20240920

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20241010

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20241203

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20250421